Development of a Radiofluorinated Adenosine A


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
30 Apr 2020
Historique:
received: 06 04 2020
revised: 28 04 2020
accepted: 28 04 2020
entrez: 6 5 2020
pubmed: 6 5 2020
medline: 5 2 2021
Statut: epublish

Résumé

The adenosine A

Identifiants

pubmed: 32366046
pii: ijms21093197
doi: 10.3390/ijms21093197
pmc: PMC7246765
pii:
doi:

Substances chimiques

Adenosine A2 Receptor Antagonists 0
Fluorine Radioisotopes 0
Receptor, Adenosine A2B 0
Fluorine-18 GZ5I74KB8G
Adenosine K72T3FS567

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Bundesministerium für Bildung und Forschung
ID : Neuroallianz D11B

Déclaration de conflit d'intérêts

The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

Références

Biochem Pharmacol. 2001 Feb 15;61(4):443-8
pubmed: 11226378
Life Sci. 2016 Dec 1;166:92-99
pubmed: 27729268
Bioorg Med Chem Lett. 2002 Feb 11;12(3):501-3
pubmed: 11814828
Naunyn Schmiedebergs Arch Pharmacol. 1989 Dec;340(6):679-83
pubmed: 2615857
J Med Chem. 2009 Jul 9;52(13):3994-4006
pubmed: 19569717
Bioorg Med Chem Lett. 2010 Mar 1;20(5):1634-7
pubmed: 20138516
Int J Mol Sci. 2019 Oct 17;20(20):
pubmed: 31627281
Pharmacol Rev. 1997 Dec;49(4):381-402
pubmed: 9443164
Purinergic Signal. 2015 Sep;11(3):389-407
pubmed: 26126429
Oncotarget. 2018 Feb 6;9(17):13593-13611
pubmed: 29568380
Pharmacol Rev. 2001 Dec;53(4):527-52
pubmed: 11734617
Nucl Med Biol. 2016 May;43(5):309-17
pubmed: 27150034
Cell Mol Neurobiol. 1983 Mar;3(1):69-80
pubmed: 6309393
ACS Med Chem Lett. 2010 Dec 20;2(3):213-8
pubmed: 24900298
Bioorg Med Chem. 2018 Sep 1;26(16):4650-4663
pubmed: 30104122
Front Chem. 2016 Aug 24;4:37
pubmed: 27606311
Nat Rev Cancer. 2013 Dec;13(12):842-57
pubmed: 24226193
Physiol Rev. 2018 Jul 1;98(3):1591-1625
pubmed: 29848236
Bioorg Med Chem Lett. 2010 Mar 1;20(5):1697-700
pubmed: 20137946
Pharmacol Rev. 2011 Mar;63(1):1-34
pubmed: 21303899
Eur J Pharm Sci. 2000;10(4):259-65
pubmed: 10838015

Auteurs

Marcel Lindemann (M)

Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany.

Rareş-Petru Moldovan (RP)

Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany.

Sonja Hinz (S)

Pharma Center Bonn, Pharmaceutical & Medicinal Chemistry, Pharmaceutical Institute, University of Bonn, 53121 Bonn, Germany.

Winnie Deuther-Conrad (W)

Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany.

Daniel Gündel (D)

Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany.

Sladjana Dukic-Stefanovic (S)

Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany.
ROTOP Pharmaka GmbH, 01328 Dresden, Germany.

Magali Toussaint (M)

Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany.

Rodrigo Teodoro (R)

Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany.

Cathleen Juhl (C)

ROTOP Pharmaka GmbH, 01328 Dresden, Germany.

Jörg Steinbach (J)

Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany.

Peter Brust (P)

Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany.

Christa E Müller (CE)

Pharma Center Bonn, Pharmaceutical & Medicinal Chemistry, Pharmaceutical Institute, University of Bonn, 53121 Bonn, Germany.

Barbara Wenzel (B)

Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH